{"pmid":32268374,"title":"Keep Taking Your ACE Inhibitors and ARBs During the COVID 19 Pandemic.","text":["Keep Taking Your ACE Inhibitors and ARBs During the COVID 19 Pandemic.","J Travel Med","Speth, Robert C","32268374"],"journal":"J Travel Med","authors":["Speth, Robert C"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32268374","week":"202015|Apr 06 - Apr 12","doi":"10.1093/jtm/taaa045","source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1663609715757678593,"score":7.9164424,"similar":[{"pmid":32250244,"title":"Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.","text":["Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.","The discovery that SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) RNA binds to the angiotensin converting enzyme (ACE)-2, which is highly expressed in the lower airways, explained why SARS-CoV-2 causes acute respiratory distress syndrome (ARDS) and respiratory failure. After this, news spread that ACEis and ARBs would be harmful in SARS-CoV-2-infected subjects. To the contrary, compelling evidence exists that the ACE-1/angiotensin(Ang)II/ATR-1 pathway is involved in SARS-CoV-2-induced ARDS, while the ACE-2/Ang(1-7)/ATR2/MasR pathway counteracts the harmful actions of AngII in the lung. A reduced ACE-1/ACE-2 ratio is, in fact, a feature of ARDS that can be rescued by human recombinant ACE-2 and Ang(1-7) administration, thus preventing SARS-CoV-2-induced damage to the lung. Based on the current clinical evidence treatment with ACE-inhibitors I (ACEis) or angiotensin receptor blockers (ARBs) continues to provide cardiovascular and renal protection in patients diagnosed with COVID-19. Discontinuing these medications may therefore be potentially harmful in this patient population.","Elife","Rossi, Gian Paolo","Sanga, Viola","Barton, Matthias","32250244"],"abstract":["The discovery that SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) RNA binds to the angiotensin converting enzyme (ACE)-2, which is highly expressed in the lower airways, explained why SARS-CoV-2 causes acute respiratory distress syndrome (ARDS) and respiratory failure. After this, news spread that ACEis and ARBs would be harmful in SARS-CoV-2-infected subjects. To the contrary, compelling evidence exists that the ACE-1/angiotensin(Ang)II/ATR-1 pathway is involved in SARS-CoV-2-induced ARDS, while the ACE-2/Ang(1-7)/ATR2/MasR pathway counteracts the harmful actions of AngII in the lung. A reduced ACE-1/ACE-2 ratio is, in fact, a feature of ARDS that can be rescued by human recombinant ACE-2 and Ang(1-7) administration, thus preventing SARS-CoV-2-induced damage to the lung. Based on the current clinical evidence treatment with ACE-inhibitors I (ACEis) or angiotensin receptor blockers (ARBs) continues to provide cardiovascular and renal protection in patients diagnosed with COVID-19. Discontinuing these medications may therefore be potentially harmful in this patient population."],"journal":"Elife","authors":["Rossi, Gian Paolo","Sanga, Viola","Barton, Matthias"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32250244","week":"202015|Apr 06 - Apr 12","doi":"10.7554/eLife.57278","keywords":["epidemiology","global health","viruses"],"source":"PubMed","locations":["ACE-1","AngII"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352136227880961,"score":118.63123},{"pmid":32187421,"title":"COVID-19: Social distancing, ACE 2 receptors, protease inhibitors and beyond?","text":["COVID-19: Social distancing, ACE 2 receptors, protease inhibitors and beyond?","Int J Clin Pract","Thomson, George","32187421"],"journal":"Int J Clin Pract","authors":["Thomson, George"],"date":"2020-03-19T11:00:00Z","year":2020,"_id":"32187421","week":"202012|Mar 16 - Mar 22","doi":"10.1111/ijcp.13503","source":"PubMed","weight":0,"_version_":1663352133797281793,"score":64.79866},{"pmid":32051570,"pmcid":"PMC7097671","title":"Novel coronavirus takes flight from bats?","text":["Novel coronavirus takes flight from bats?","Nat Rev Microbiol","York, Ashley","32051570"],"journal":"Nat Rev Microbiol","authors":["York, Ashley"],"date":"2020-02-14T11:00:00Z","year":2020,"_id":"32051570","week":"20207|Feb 10 - Feb 16","doi":"10.1038/s41579-020-0336-9","source":"PubMed","topics":["Mechanism","Transmission"],"weight":1,"_version_":1663352134675988481,"score":59.995865},{"pmid":32259575,"title":"BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19.","text":["BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19.","Int J Antimicrob Agents","Praveen, D","Chowdary, Puvvada Ranadheer","Aanandhi, M Vijey","32259575"],"journal":"Int J Antimicrob Agents","authors":["Praveen, D","Chowdary, Puvvada Ranadheer","Aanandhi, M Vijey"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259575","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.ijantimicag.2020.105967","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663450393541083137,"score":58.189148},{"pmid":32266993,"title":"Reporting of all cardiac medications and their outcome in COVID - 19.","text":["Reporting of all cardiac medications and their outcome in COVID - 19.","We read with much interest the article \"Organ- protective effect of Angiotensin Converting Enzyme 2 and its Effect on the prognosis of COVID -19\" by Cheng et al in your esteemed Journal. Authors have discussed the theoretical basis of Angiotensin Converting Enzyme 2 in improving outcome of COVID - 19 patients(1) . This article is protected by copyright. All rights reserved.","J Med Virol","Mishra, Ajay Kumar","Sahu, Kamal Kant","Lal, Amos","32266993"],"abstract":["We read with much interest the article \"Organ- protective effect of Angiotensin Converting Enzyme 2 and its Effect on the prognosis of COVID -19\" by Cheng et al in your esteemed Journal. Authors have discussed the theoretical basis of Angiotensin Converting Enzyme 2 in improving outcome of COVID - 19 patients(1) . This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Mishra, Ajay Kumar","Sahu, Kamal Kant","Lal, Amos"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32266993","week":"202015|Apr 06 - Apr 12","doi":"10.1002/jmv.25843","source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1663609715794378752,"score":42.820652}]}